BMJ Open Ophthalmology · 2019 · 19 citations · 15 references
MedicineOncologyOphthalmologyOcular DiseaseOcular OncologyOcular PharmacologyOcular TumorsRetinal DiseaseRetinal DisordersRetinal PathologyRetinal PharmacotherapyRetinal Vascular DiseaseBiomarkersDaily DosingPropranolol TherapyRetinal TumorsVascular Endothelial Growth FactorVhl Gene AlterationsVon Hippel-lindau DiseaseVon Hippel-lindau Syndrome
BACKGROUND: gene. Retinal hemangioblastoma is one of the most common tumours, and when it appears near the optic nerve, its treatment is challenging and risky. To date, no treatment has proven effective in changing the course of the disease. This study was designed to evaluate the safety and effectiveness of propranolol in controlling these tumours. METHODS: Seven patients were included. All patients took a daily dose of 120 mg of propranolol for 1 year. Clinical variables were assessed at baseline, and at 1, 3, 6, 9 and 12 months. The primary endpoint of the study was the number and size of retinal hemangioblastomas. On every visit, retinal outcomes and blood biomarkers (such as vascular endothelial growth factor (VEGF) and miR210) were analysed. RESULTS: Number and size of retinal hemangioblastomas remained stable in all patients. All of them had initially increased levels of VEGF and miR210. There was a gradual reabsorption of retinal exudation in two patients, correlating with a progressive decrease of both biomarkers. The only adverse effect reported was hypotension in one patient. CONCLUSIONS: Propranolol could be used to treat retinal hemangioblastomas in VHL patients, although more studies are needed to determine the ideal dose and long-term effect. VEGF and miR210 should be explored as biomarkers of disease activity. As far as we know, these are the first biomarkers proposed to monitor the VHL disease activity. TRIAL REGISTRATION NUMBER: 2014-003671-30.
15
Beta Blockers and Breast Cancer Mortality: A Population- Based Study
Thomas I. Barron, Roisín M. Connolly, Linda Sharp et al. · Journal of Clinical Oncology · 2011 · 518 citations
Medicine, Oncology, Pharmacology +14
Propranolol for Off-label Treatment of Patients With Melanoma
Vincenzo De Giorgi, Marta Grazzini, Silvia Benemei et al. · JAMA Oncology · 2017 · 192 citations · Full text